Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 A Joint Statement from the European Association of Urology Renal Cell Cancer Guidelines Panel and the International Kidney Cancer Coalition: The Rejection of Ipilimumab and Nivolumab for Renal Cancer by the Committee for Medicinal Products for Human Use Does not Change Evidence-based Guideline Recommendations.

Literature DB >> 30201510

A Joint Statement from the European Association of Urology Renal Cell Cancer Guidelines Panel and the International Kidney Cancer Coalition: The Rejection of Ipilimumab and Nivolumab for Renal Cancer by the Committee for Medicinal Products for Human Use Does not Change Evidence-based Guideline Recommendations.

Axel Bex¹, Laurence Albiges², Michael Staehler³, Karim Bensalah⁴, Rachel H Giles⁵, Saeed Dabestani⁶, Fabian Hofmann⁷, Milan Hora⁸, Markus A Kuczyk⁹, Thomas B Lam¹⁰, Lorenzo Marconi¹¹, Axel S Merseburger¹², Sergio Fernández-Pello¹³, Rana Tahbaz¹⁴, Yasmin Abu-Ghanem¹⁵, Alessandro Volpe¹⁶, Börje Ljungberg¹⁷, Bernard Escudier¹⁸, Thomas Powles¹⁹.

Abstract

Entities: Chemical Disease Species

Mesh：

Substances：

Year: 2018 PMID： 30201510 DOI： 10.1016/j.eururo.2018.08.029

Source DB: PubMed Journal: Eur Urol ISSN： 0302-2838 Impact factor: 20.096

Keyword Cloud
Cited

× No keyword cloud information.

1 in total

1. Combining Immune Checkpoint and VEGFR Inhibition in Favorable Risk and Elderly Patients With Metastatic Renal Cell Carcinoma.

Authors: Andreas Varkaris; Wenxin Xu; Roger B Davis; Brian Healy; David F McDermott
Journal: Clin Genitourin Cancer Date: 2019-12-05 Impact factor: 2.872

1 in total